Rexulti falls short of goal in late-stage bipolar disorder studies
Lundbeck’s Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies.
Read More
Tag: rexulti
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
